Poseidonol in the treatment of hyperlipidemia in patients with type 2 diabetes mellitus
Panchenko, V.M.; Ershov, A.A.; Isaev, V.A.; ZImovchenko, G.S.; Chernova, G.I.
Klinicheskaia Meditsina 79(6): 47-49
2001
ISSN/ISBN: 0023-2149 PMID: 11521381 Document Number: 532196
Thirty five patients with type 2 diabetes mellitus complicated by cardiovascular diseases received 6-month treatment for hyperlipidemia with poseidonol that represents a set of essential polyunsaturated fatty acids. This yielded good results as 11.6%-, 30%- and 24.2% decreases in the levels of cholesterol, triglycerides, and beta-lipoprotein, respectively, and a 9.9%- increase in alpha-lipoprotein. Lipid metabolism became normal in 34.2% of the patients, the remaining had positive changes as normalization of 1 to 3 lipid parameters. The tolerance of the agent was good, no negative effect on hepatic and renal functions was found.